To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT05814393

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05814393
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05814393. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-03 (actual); primary completion 2024-05-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Treatment Period(JW0201)
Intervention (Drug)
Treatment Period(Placebo)
Intervention (Drug)
Extension Period(JW0201)
Lead sponsor
JW Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct05814393
Content hash
c15329ee1c0552293a10062fcfece22862213510c62ac49095d31d8a4c306cdf